These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

474 related articles for article (PubMed ID: 30619288)

  • 1. Ovarian Cancer-Intrinsic Fatty Acid Synthase Prevents Anti-tumor Immunity by Disrupting Tumor-Infiltrating Dendritic Cells.
    Jiang L; Fang X; Wang H; Li D; Wang X
    Front Immunol; 2018; 9():2927. PubMed ID: 30619288
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ER Stress Sensor XBP1 Controls Anti-tumor Immunity by Disrupting Dendritic Cell Homeostasis.
    Cubillos-Ruiz JR; Silberman PC; Rutkowski MR; Chopra S; Perales-Puchalt A; Song M; Zhang S; Bettigole SE; Gupta D; Holcomb K; Ellenson LH; Caputo T; Lee AH; Conejo-Garcia JR; Glimcher LH
    Cell; 2015 Jun; 161(7):1527-38. PubMed ID: 26073941
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blockade of fatty acid synthase induces ubiquitination and degradation of phosphoinositide-3-kinase signaling proteins in ovarian cancer.
    Tomek K; Wagner R; Varga F; Singer CF; Karlic H; Grunt TW
    Mol Cancer Res; 2011 Dec; 9(12):1767-79. PubMed ID: 21970855
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Immunological Role of CDK4/6 and Potential Mechanism Exploration in Ovarian Cancer.
    Liu C; Huang Y; Cui Y; Zhou J; Qin X; Zhang L; Li X; Li Y; Guo E; Yang B; Li X; Fan J; Li X; Fu Y; Liu S; Hu D; Xiao R; Wang Z; Dou Y; Wang W; Li W; Yang X; Liu J; Peng W; Qin T; You L; Lu F; Sun C
    Front Immunol; 2021; 12():799171. PubMed ID: 35095879
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fatty acid synthase expression associated with NAC1 is a potential therapeutic target in ovarian clear cell carcinomas.
    Rahman MT; Nakayama K; Rahman M; Katagiri H; Katagiri A; Ishibashi T; Ishikawa M; Iida K; Nakayama N; Otsuki Y; Nakayama S; Miyazaki K
    Br J Cancer; 2012 Jul; 107(2):300-7. PubMed ID: 22653145
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential requirement for de novo lipogenesis in cholangiocarcinoma and hepatocellular carcinoma of mice and humans.
    Li L; Che L; Tharp KM; Park HM; Pilo MG; Cao D; Cigliano A; Latte G; Xu Z; Ribback S; Dombrowski F; Evert M; Gores GJ; Stahl A; Calvisi DF; Chen X
    Hepatology; 2016 Jun; 63(6):1900-13. PubMed ID: 26910791
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multi-level suppression of receptor-PI3K-mTORC1 by fatty acid synthase inhibitors is crucial for their efficacy against ovarian cancer cells.
    Wagner R; Stübiger G; Veigel D; Wuczkowski M; Lanzerstorfer P; Weghuber J; Karteris E; Nowikovsky K; Wilfinger-Lutz N; Singer CF; Colomer R; Benhamú B; López-Rodríguez ML; Valent P; Grunt TW
    Oncotarget; 2017 Feb; 8(7):11600-11613. PubMed ID: 28086243
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TRANCE- and CD40 ligand-matured dendritic cells reveal MHC class I-restricted T cells specific for autologous tumor in late-stage ovarian cancer patients.
    Schlienger K; Chu CS; Woo EY; Rivers PM; Toll AJ; Hudson B; Maus MV; Riley JL; Choi Y; Coukos G; Kaiser LR; Rubin SC; Levine BL; Carroll RG; June CH
    Clin Cancer Res; 2003 Apr; 9(4):1517-27. PubMed ID: 12684428
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Destabilization of Fatty Acid Synthase by Acetylation Inhibits De Novo Lipogenesis and Tumor Cell Growth.
    Lin HP; Cheng ZL; He RY; Song L; Tian MX; Zhou LS; Groh BS; Liu WR; Ji MB; Ding C; Shi YH; Guan KL; Ye D; Xiong Y
    Cancer Res; 2016 Dec; 76(23):6924-6936. PubMed ID: 27758890
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ovarian cancer progression is controlled by phenotypic changes in dendritic cells.
    Scarlett UK; Rutkowski MR; Rauwerdink AM; Fields J; Escovar-Fadul X; Baird J; Cubillos-Ruiz JR; Jacobs AC; Gonzalez JL; Weaver J; Fiering S; Conejo-Garcia JR
    J Exp Med; 2012 Mar; 209(3):495-506. PubMed ID: 22351930
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fatty acid synthase inhibition engages a novel caspase-2 regulatory mechanism to induce ovarian cancer cell death.
    Yang CS; Matsuura K; Huang NJ; Robeson AC; Huang B; Zhang L; Kornbluth S
    Oncogene; 2015 Jun; 34(25):3264-72. PubMed ID: 25151963
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fatty acid synthase: A key driver of ovarian cancer metastasis and a promising therapeutic target.
    Ahmad N; Moton S; Kuttikrishnan S; Prabhu KS; Masoodi T; Ahmad S; Uddin S
    Pathol Res Pract; 2024 Aug; 260():155465. PubMed ID: 39018927
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of fatty acid synthase attenuates CD44-associated signaling and reduces metastasis in colorectal cancer.
    Zaytseva YY; Rychahou PG; Gulhati P; Elliott VA; Mustain WC; O'Connor K; Morris AJ; Sunkara M; Weiss HL; Lee EY; Evers BM
    Cancer Res; 2012 Mar; 72(6):1504-17. PubMed ID: 22266115
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In situ stimulation of CD40 and Toll-like receptor 3 transforms ovarian cancer-infiltrating dendritic cells from immunosuppressive to immunostimulatory cells.
    Scarlett UK; Cubillos-Ruiz JR; Nesbeth YC; Martinez DG; Engle X; Gewirtz AT; Ahonen CL; Conejo-Garcia JR
    Cancer Res; 2009 Sep; 69(18):7329-37. PubMed ID: 19738057
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Crosstalk between osteoprotegerin (OPG), fatty acid synthase (FASN) and, cycloxygenase-2 (COX-2) in breast cancer: implications in carcinogenesis.
    Goswami S; Sharma-Walia N
    Oncotarget; 2016 Sep; 7(37):58953-58974. PubMed ID: 27270654
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fatty acid synthase is a prognostic marker and associated with immune infiltrating in gastric cancers precision medicine.
    Zhou Y; Su W; Liu H; Chen T; Höti N; Pei H; Zhu H
    Biomark Med; 2020 Feb; 14(3):185-199. PubMed ID: 31904263
    [No Abstract]   [Full Text] [Related]  

  • 17. Fatty acid synthase is a metabolic marker of cell proliferation rather than malignancy in ovarian cancer and its precursor cells.
    Veigel D; Wagner R; Stübiger G; Wuczkowski M; Filipits M; Horvat R; Benhamú B; López-Rodríguez ML; Leisser A; Valent P; Grusch M; Hegardt FG; García J; Serra D; Auersperg N; Colomer R; Grunt TW
    Int J Cancer; 2015 May; 136(9):2078-90. PubMed ID: 25302649
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction of tolerogenic dendritic cells by activated TGF-β/Akt/Smad2 signaling in RIG-I-deficient stemness-high human liver cancer cells.
    Zhong M; Zhong C; Cui W; Wang G; Zheng G; Li L; Zhang J; Ren R; Gao H; Wang T; Li X; Che J; Gohda E
    BMC Cancer; 2019 May; 19(1):439. PubMed ID: 31088527
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fatty acid synthase overexpression: target for therapy and reversal of chemoresistance in ovarian cancer.
    Bauerschlag DO; Maass N; Leonhardt P; Verburg FA; Pecks U; Zeppernick F; Morgenroth A; Mottaghy FM; Tolba R; Meinhold-Heerlein I; Bräutigam K
    J Transl Med; 2015 May; 13():146. PubMed ID: 25947066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reactive Neutrophil Responses Dependent on the Receptor Tyrosine Kinase c-MET Limit Cancer Immunotherapy.
    Glodde N; Bald T; van den Boorn-Konijnenberg D; Nakamura K; O'Donnell JS; Szczepanski S; Brandes M; Eickhoff S; Das I; Shridhar N; Hinze D; Rogava M; van der Sluis TC; Ruotsalainen JJ; Gaffal E; Landsberg J; Ludwig KU; Wilhelm C; Riek-Burchardt M; Müller AJ; Gebhardt C; Scolyer RA; Long GV; Janzen V; Teng MWL; Kastenmüller W; Mazzone M; Smyth MJ; Tüting T; Hölzel M
    Immunity; 2017 Oct; 47(4):789-802.e9. PubMed ID: 29045907
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.